Zanidatamab Combined With Chemotherapy as Neoadjuvant/Conversion Therapy for HER2-Positive (IHC 3+ or IHC 2+) Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a Phase II Open-Label Study

Name: Zanidatamab Combined With Chemotherapy as Neoadjuvant/Conversion Therapy for HER2-Positive (IHC 3+ or IHC 2+) Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a Phase II Open-Label Study
License: Public Domain

Zhifeng Zhao, PhD

ClinicalTrials.gov · Datasets · License: Public Domain

Open Source ↗

gastric cancer, gastroesophageal junction adenocarcinoma, her2-positive gastric cancer

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 394773
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.